NCT01190189 - Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

November 23, 2017

Study Completion Date

November 23, 2017

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

GSK580299 (Cervarix)

3-dose schedule intramuscularly vaccination

Trial Locations (28)

15106

GSK Investigational Site, Carnegie

15236

GSK Investigational Site, Pittsburgh

16507

GSK Investigational Site, Erie

16508

GSK Investigational Site, Erie

28562

GSK Investigational Site, New Bern

30912

GSK Investigational Site, Augusta

33134

GSK Investigational Site, Coral Gables

33136

GSK Investigational Site, Miami

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

44122

GSK Investigational Site, Cleveland

52242

GSK Investigational Site, Iowa City

67207

GSK Investigational Site, Wichita

68131

GSK Investigational Site, Omaha

77030

GSK Investigational Site, Houston

80045

GSK Investigational Site, Aurora

80401

GSK Investigational Site, Golden

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

98801

GSK Investigational Site, Wenatchee

03756

GSK Investigational Site, Lebanon

T5A 4L8

GSK Investigational Site, Edmonton

V6H 3N1

GSK Investigational Site, Vancouver

B3K 6R8

GSK Investigational Site, Halifax

B2N 1L2

GSK Investigational Site, Truro

N2L 6H6

GSK Investigational Site, Waterloo

G1S 2L6

GSK Investigational Site, Québec

J1H 1Z1

GSK Investigational Site, Sherbrooke